Download Poster Session A - American Association for Cancer Research

Poster Session A
Friday, September 25, 2015
12:30 p.m.–2:30 p.m.
Overlook
A01, PR01 Structural mechanism of sequence-specific 5-methylcytosine (5mC) recognition by AP1 transcription factors. Samuel Hong, Emory University, Atlanta, GA, United States.
A02 The HER4 BH3-only protein and tumor suppressor is epigenetically silenced in endocrine
refractory and triple negative breast cancers. Frank Jones, Tulane University, New Orleans, LA,
United States.
A03 Krüppel-like Transcription Factor-10 (KLF10) suppresses the TGFβ-induced epithelial-tomesenchymal transition. Vivek Kumar Mishra, University Medical Center Göttingen, Göttingen,
Germany.
A04 Modulation of SAGA mediated nucleosome acetylation by linker DNA and activator. Chitvan
Mittal, Iowa State University, Ames, IA, United States.
A05 Angiogenin contributes to bladder cancer tumorigenesis by facilitating p53/DNMT3bmediated activation of MMP2. Rafael Peres, University of Hawaii Cancer Center, Honolulu, HI, United
States.
A06, PR02 Transcriptional regulation mediated by biochemically distinct forms of SWI/SNF. Jesse
Raab, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
A07 Histone demethylase NO66 overexpression promotes proliferative and invasive potential of
prostate cancer cells and causes osteolytic bone lesions in mice. Krishna Sinha, University of Texas
MD Anderson Cancer Center, Houston, TX, United States.
A08, PR06 Analysis of enhancer transcription reveals novel gene regulatory networks in breast
cancer. Hector Franco, The Cecil H. and Ida Green Center for Reproductive Biology Sciences, UT
Southwestern Medical Center, Dallas, TX, United States.
A09 Functional characterization of fine-mapped prostate cancer SNPs. Yu (Phoebe) Guo, University
of Southern California, Los Angeles, CA, United States.
A10 High fat diet enhances MYC-driven prostate cancer through epigenomic and metabolomic
rewiring. David Labbé, Dana-Farber Cancer Institute, Boston, MA, United States.
A11 Functional Characterization of Risk Enhancers associated with Colorectal Cancer (CRC)
using CRISPR/Cas9. Yu Gyoung Tak, USC, Los Angeles, CA, United States.
A12, PR12 MED12 methylation by CARM1 sensitizes human breast cancer cells to chemotherapy
drugs. Wei Xu, University of Wisconsin, Madison, WI, United States.
A13 Androgen receptor functions as an adaptor protein for recruitment of protein phosphatase 1a
to chromatin and CDK9 mobilization. Steven Balk, Beth Israel Deaconess Medical Center, Boston, MA,
United States.
Poster Session A
Friday, September 25, 2015
12:30 p.m.–2:30 p.m.
Overlook
A14, PR08 GC skew defines distinct RNA polymerase pause sites in CpG island promoters..
Joshua Bell, Emory University, Atlanta, GA, United States.
A15 The integrin α6β4 promotes pancreatic cancer invasion by altering DNA repair-mediated
epigenetics. Brittany Carpenter, University of Kentucky, Lexington, KY, United States.
A16 Different epigenetic mechanisms involved in the regulation of SFRP1 gene in prostate cancer.
Pilar García-Tobilla, National Institute of Genomic Medicine, Mexico City, Mexico.
A17 ATXN7L3B interferes with deubiquitinase activity of SAGA complex. Wenqian Li, The University
of Texas MD Anderson Cancer Center, Houston, TX, United States.
A18 Mismatch repair proteins recruit DNA methyltransferase 1 to sites of oxidative DNA damage.
Heather O'Hagan, Indiana University, Bloomington, IN, United States.
A19 A NOVEL MECP2 ACETYLATION SITE REGULATES BINDING WITH ATRX AND HDAC1.
Somnath Pandey, TTUHSC - Lubbock, Lubbock, TX, United States.
A20 Epigenomic analysis of inhibition of histone demethylase LSD1 reveals novel enhancer
elements in Ewing sarcoma cells. Ranajeet Saund, The Research Institute, Nationwide Childrens
Hospital, Columbus, OH, United States.
A21 The role of SOX4 in epithelial to mesenchymal transition in prostate cancer. Nitya Sharma,
Emory University, Atlanta, GA, United States.
A22 Cell growth regulation of gain-of-function mutant p53 via miRNAs on metabolic inhibition.
Young-Ah Suh, Asan Medical Center, Seoul, Korea, Republic Of.
A23 High mobility group N proteins modulate chromatin regulatory sites and gene expression
during LPS-induced B-cell activation. Shaofei Zhang, National Institutes of Health, Bethesda, MD,
United States.
A24 PBRM1 alteration in clear cell renal cell carcinoma increases tumorigenicity through
ALDH1A1 upregulation. David Schoenfeld, Columbia University, New York, NY, United States.
A25 A Novel Spectroscopic Technology to Image the Native Chromatin Nanostructure in Live
Cells. Yolanda Stypula, Northwestern University, Evanston, IL, United States.
A26, PR07 The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within
large topological domains. Erica Walsh, Brigham and Women's Hospital, Harvard Medical School,
Boston, MA, United States.
Poster Session A
Friday, September 25, 2015
12:30 p.m.–2:30 p.m.
Overlook
A27 DNA Methylation and Transcriptional Dysregulation of miRNA-137 and -193a in Premalignant
Oral Lesions and Oral Squamous Cell Carcinoma. Vikram Bhatia, King George’s Medical University,
Lucknow, U.P., India.
A28 Expanding the TLX1 regulome in T-cell acute lymphoblastic leukemia towards long noncoding RNAs. Kaat Durinck, Center for Medical Genetics, Ghent University, Ghent, Belgium.
A29 PIWI-like proteins and piRNAs in breast cancer cell proliferation and migration. Qidong Hu,
National University of Singapore, Singapore, Singapore.
A30 TUG1, a Notch-regulated non-coding RNA maintains stemness in gliomas. YUTAKA KONDO,
Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
A31 The long non-coding RNA SPRY4-IT1 regulates melanoma and melanocytes development in
human. Ranjan Perera, Sanford-Burnham Medical Research Institute, Orlando, FL, United States.
A32 The Role of microRNA in the Regulation of DUSP16 Gene and JNK Family in Hepatocellular
Carcinoma Patients. Marwa Tantawy, Children's Cancer Hospital 57357, Cairo, Egypt.
A33 Mediator is an intrinsically dynamic complex critical to Hsf1-activated transcription. Jayamani
Anandhakumar, Louisiana State University Health Sciences Center, Shreveport, LA, United States.
A34, PR03 Exploring the link between Kras and histone acetylation. Alessandro Carrer, Abramson
Family Cancer Research Institute, Philadelphia, PA, United States.
A35 Innovative Technologies for Cancer Research: NCI Strategy for Supporting Next Generation
of Tools Needed Against Cancer. Tony Dickherber, National Cancer Institute, Bethesda, MD, United
States.
A36 Investigating contribution of the Mediator Cdk8 module subunits Med12, Med13 and Med13L
to Cdk8 oncogenic functions in colon cancer cells. Emilia Kuuluvainen, University of Helsinki,
Helsinki, Finland.
A37 Aberrant DNA methylation of HTATIP2 and UCH-L1 as prognostic and predictive biomarkers
for cholangiocarcinoma. Temduang Limpaiboon, Centre for Research and Development of Medical
Diagnostic Laboratories, Khon Kaen University, Khon Kaen, Khon Kaen, Thailand.
A38 Interconnections between transcription, cotranscriptional splicing and decay of U12-type
intron containing mRNAs. Elina Niemela, University of Helsinki, Helsinki, Finland.
A39 H3K9 methyltransferases G9a/Glp link the chromatin regulation of lung adenocarcinoma
tumor propagating cells and lung bronchiolaveolar stem cells. Samuel Rowbotham, Boston
Children's Hospital, Boston, MA, United States.
Poster Session A
Friday, September 25, 2015
12:30 p.m.–2:30 p.m.
Overlook
A40 Emergence of CD47- high expression cells confers enhanced tumorigenicity upon KDM6B
suppression in pancreatic cancer. Keisuke Tateishi, University of Tokyo, Tokyo, Japan.
A41 TANK inhibits genotoxic NF-κB activation by facilitating MCPIP1/USP10-dependent
deubiquitination of TRAF6. Wei Wang, University of Tennessee Health Science Center, Memphis, TN,
United States.
A42 Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in
hepatocellular carcinoma promotes cancer metastasis. Chun-Ming Wong, The University of Hong
Kong, Hong Kong, Hong Kong.
A43 DNA repair by non-homologous end joining induced gene silencing via DNA
hypermethylation. Brittany Allen, University of Central Florida, Orlando, FL, United States.
A44 The role of PHF6 in maintaining pre-B cell commitment in B-cell acute lymphoblastic
leukemia. Jordan Bartlebaugh, Massachusetts Institute of Technology, Cambridge, MA, United States.
A45 Connecting alternative transcript usage with differential DNA methylation in aggressive
prostate cancer. Jeffrey Bhasin, Cleveland Clinic Lerner College of Medicine at Case Western Reserve
University, Cleveland, OH, United States.
A46 Effects of genistein supplementation on genome-wide DNA methylation and gene expression
in patients with localized prostate cancer. Birdal Bilir, Emory University, Atlanta, GA, United States.
A47 Chromatin remodeling factor SMARCA4 as a predictive biomarker of cisplatin therapy in nonsmall cell lung cancer. Arup Chakraborty, Ohio State University, Columbus, OH, United States.
A48 Cbx8 acts non-canonically in breast cancer to promote Notch signaling. Chi-Yeh Chung, Icahn
School of Medicine at Mount Sinai, New York, NY, United States.
A49 The chromatin landscape of stem cells confers a permissive environment for cancer
development. Ian Davis, University of North Carolina, Chapel Hill, NC, United States.
A50 The identification of an Ets1-driven gene signature in head and neck squamous cell
carcinoma. Christian Gluck, State University of New York at Buffalo, Buffalo, NY, United States.
A51 DNA methylation in tumor, adjacent non-tumorous and normal breast tissues. Chunyan He,
Indiana University, Indianapolis, IN, United States.